Background and aims:
Introduction
Biologics have improved the treatment of various inflammatory diseases, including inflammatory bowel disease (IBD). Biosimilars were first introduced in the European market in the early 2010s, and the initial approach to them of the European Crohn's and Colitis Organisation (ECCO) and many national IBD medical societies was rather cautious. 1 Further scientific evidence on the efficacy and safety of biosimilars, such as data from a large randomized control trial NOR-SWITCH, which included over 400 Norwegian patients with immune-mediated diseases and examined efficacy, safety and immunogenicity when switching from an infliximab originator to a less expensive biosimilar CT-P13 and showed that switching from the originator to the biosimilar was not inferior to continued originator treatment, 2 have brought about a deeper understanding of the characteristics, development and regulatory approval of biosimilars. The more recent position statement by ECCO is more confident in terms of safety and efficacy of biosimilars, and considers switching from an originator acceptable. 3 Patients with IBD have also been cautious regarding biosimilars. Our previous Biologics and Biosimilars survey, carried out in 2014-15 to assess patients' 1 Inserm 1256 Ngere and Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandoeuvre-lès-Nancy, France 2 European Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium 3 IBD Center, Department of Gastroenterology, Humanitas University, Milan, Italy knowledge about biosimilars and issues around them, showed that awareness on biosimilars was insufficient and there was much suspicion around them. 4 It has long been recognized that patient perception is an important source of information when developing actions for quality improvement in health care, and that patient data can be used as a supplementary quality of care indicator. 5, 6 Therefore, the purpose of this survey was to find out whether patients' perceptions on biosimilars have changed since our previous survey.
Materials and methods
The questionnaire
The original questionnaire, used in the previous survey, 4 was developed by the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) in collaboration with experts in the field (Laurent Peyrin-Biroulet, Xavier Roblin, Silvio Danese and Luisa Avedano), and it consisted of 14 questions. It was carried out as an online survey in 2014-2015 and offered in nine languages (English, French, Italian, German, Spanish, Russian, Greek, Turkish and Hebrew). The national member associations of EFCCA were responsible for informing their membership about the survey. As the survey revealed that patients with IBD had doubt and concerns about the safety and efficacy of biosimilars, the decision was made to carry out a follow-up survey to find out whether patients' perceptions have changed in recent years.
For the follow-up, five questions were added in the original questionnaire, and the final questionnaire therefore included 19 questions. Apart from English, the questionnaire was translated into seven languages and was available online from July to December 2018 on the EFCCA website. As during the previous survey, the national patient associations were responsible for informing their members about the survey. After basic demographic questions, only those respondents who had heard of biosimilars continued to the biosimilar-specific questions.
The participants
The participants of the survey were members of EFCCA member associations or persons following the communications of these associations. The recruitment was self-selective.
Statistical considerations
The response variables were categorical. Explanatory variables were integer age and binary disease. A binary logit model was used for the response variables that had only two possible values and a generalized logit model for the variables that had more than two possible values. In the case of the age or disease variable not being statistically significant, the variable with the greater p-value was removed from the model. In some questions, some observations were deleted as a result of missing values for the response or explanatory values. Some of the data from the previous survey were presented differently than previously to better allow for a comparison.
Results

Respondent demographics
A total of 1643 respondents completed the survey. Some 61.8% (n ¼ 1015) of them had Crohn's disease (CD), 36.8% (n ¼ 604) had ulcerative colitis (UC), 1.1% (n ¼ 18) another inflammatory disease and 0.4% (n ¼ 6) a rheumatic disease; this was very similar to the previous survey. Only respondents with IBD (n ¼ 1619) were included in the analysis. Most respondents (45.5%) were 21-40 years old. Of the respondents, 2.0% were diagnosed in 1980 or before, 7.7% between 1981 and 1990, 16.2% between 1991 and 2000, 31.7% between 2001 and 2010, and 41.6% in 2011 or later. Most respondents were from Europe (78.9%), followed by Asia (7.8%), South America (6.8%) and Africa (5.3%). Because of the limited participation from other continents compared with Europe, a comparison between continents was left out.
Exposure to biologics and biosimilars (Questions 1-3)
Slightly more respondents than in the previous survey were currently being treated with anti-TNF, and slightly more had had the therapy discontinued due to either inefficacy or side effects. Significantly more respondents than in the previous survey had heard of biosimilars (44.0% in the current vs. 36.2% in the previous survey, p ¼ 0.0001). Only those who had heard of biosimilars (n ¼ 596) continued to the biosimilarspecific questions (Questions 4-19). For the overall results of Questions 1-3 and comparison with the previous survey, see Table 1 .
Concerns about biosimilars (Question 4)
As in the previous survey, the most common biosimilarrelated concerns remained safety and efficacy. The worry about efficacy was significantly more common. For overall results and comparison with the previous survey, see Table 2 .
Price, extrapolation and biosimilars in the market (Questions 5-7)
Respondents were surveyed on their views regarding the lower price of biosimilars, extrapolation, and biosimilars entering the market. Respondents were able to choose more than one option in the three questions. As they were able to only choose one option in these questions in the previous survey, the results are not statistically comparable, but demonstrate a more reliable division of opinions as respondents were able to choose all that applied. For results and comparison with the previous survey, see Table 3 .
Interchangeability with reference drug and same pharmacological name; biosimilars' impact on IBD management (Questions 8-10)
In Question 8, respondents were surveyed on their views on interchangeability. In Question 9, it was explained to the respondents that the biosimilars will have the same pharmacological name as the reference drug, so there will be no way to distinguish it from the reference drug. In Question 10, respondents were asked about their views regarding biosimilars' impact on IBD management. For overall results and comparison with the previous survey, see Table 4 . Respondents were surveyed about their views on being prescribed biosimilars by their treating physician, on the pharmacist handing out the biosimilar, changing the initial prescription without the consent of the prescribing physician, and regarding their behaviour after starting a biosimilar treatment. For results and comparison with the previous survey, see Table 5 .
Biosimilars and generic drugs (Questions 14 and 15)
Respondents were surveyed about their perceptions regarding biosimilars and generic drugs. Results and comparisons with the previous survey are shown in Table 6 . The biosimilar will be less expensive than the reference drug, you think that (it is possible to choose more than one option):
(a) These are good news because more patients will be treated with biologics A question was added in the current survey about how the respondents would grade, on a scale from 0 (very poor) to 10 (excellent), the quality of information/ communication that they received so far on biosimilars.
Results are shown in Figure 1 .
In another new question, the respondents were asked whether they have been systematically informed by their doctor if they were receiving biosimilars. Some 23.0% of the respondents felt they had, and 35.1% felt they had not; for 41.9%, the question was not applicable.
Biosimilar efficacy and side effects in patients who have been switched (Questions 18 and 19, n ¼ 570 and n ¼ 569, respectively)
In two more new questions, respondents were asked about their experiences on efficacy and side effects if they had been switched from Remicade to a biosimilar. Some 10.2% of the respondents reported to be experiencing the same efficacy, and 12.8% reported not. For 77.0% of the respondents, the question was not applicable. Some 7.9% of the respondents reported Table 4 . Results of Questions 8-10 and comparison with the previous survey. Underlined: p ¼ 0.0002, in italics: p < 0.0001, otherwise p > 0.05. In Question 8, option (a) was divided into two different questions in the previous survey but combined into one in this one; the results of the previous survey were changed for the presentation in the current one. In Question 9, the wording was changed from ''Do you think that the arrival of biosimilars will have an impact on the management of your disease?'' in the previous survey to ''Do you think that the arrival of biosimilars will have an impact on the management of IBD?'' in the current one. experiencing more side effects and 13.2% not experiencing more side effects than before. For 78.9% of the respondents, the question was not applicable.
Discussion
In our previous survey, 4 one of the most striking results was the patients' unfamiliarity with biosimilars; 45.0% of the respondents were currently treated with biologic medications, but only 36.2% had heard of biosimilars. This time, more respondents (58.9%) were currently being treated with biologics, and significantly more (44.0%) had also heard of biosimilars. Still, a large proportion of those being treated with biologics were unfamiliar with biosimilars. Furthermore, the respondents of the previous survey seemed generally sceptical about biosimilars; only 26.4% of the respondents had no specific concerns. In the current survey, 22% had no specific concerns; however, the difference was not statistically significant. Clearly, patient information and education in recent years has not greatly succeeded in clearing suspicions and worries around biosimilars. Future initiatives should focus on delivering more awareness and information. Interestingly, although the worries remain, respondents were significantly more likely to believe that biosimilars would have an impact on the management of IBD in the current survey than in the previous one.
These findings may explain, at least in part, the nocebo effect, defined as a negative effect of a pharmacological or non-pharmacological medical treatment that is induced by patients' expectations, and that is unrelated to the physiological action of the treatment. 7, 8 Furthermore, it seems that patients with immunemediated inflammatory diseases may in general have poorer knowledge than oncology patients on biosimilar-related topics. In a study 9 of over 600 French patients treated for rheumatic inflammatory diseases that assessed patients' information about biosimilars, it was found that biosimilars were largely unknown to patients: 57% of the respondents did not know what biosimilars were. Respondents also worried about efficacy (60%), safety (57%) and non-similar molecular structure (46%) compared with the originator. On the other hand, an American study 10 on 79 oncology patients showed that over 70% of the respondents were aware of the correct definition of biosimilars. The study showed a good level of knowledge and awareness among the participants. While the questionnaire used in these surveys was not identical to ours, the results give an idea of differences in awareness between oncology patients and patients with immune-mediated diseases. This is important, as information and a good understanding on biosimilars seem to be associated with better adherence to biosimilars. 9 The new questions in the current survey showed that patients experience dissatisfaction in the quality and sufficiency of information and communication regarding biosimilars. Future research should clarify exactly what patients feel is missing, and how the missing information could be brought to the patients in the most efficient way. Initiatives should be directed at both patients and health care personnel to improve biosimilar awareness among patients with IBD. This survey had some limitations. The survey was self-selective, only available online and in eight languages, which may have affected the participant population. Some questions were rephrased or response options altered from the previous survey, which made the previous and current survey partly statistically incomparable. Furthermore, differences in availability of treatment modalities between countries may have affected the responses of the participants.
In conclusion, the current survey shows that although awareness on biosimilars has somewhat improved, there is room for larger improvements. Furthermore, although patients with IBD are more familiar with biosimilars, worrying about their efficacy as compared with the reference drugs is significantly more common than in our previous survey. While awareness-raising around biosimilars has succeeded, it has failed in clearing the air of suspicions around biosimilars. Stronger cooperation between patient organisations and health care practitioners could help improve the situation. 
